BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and antitrypanosomal activity of heteroaryl-based 1,2,4-triazole and 1,3,4-oxadiazole derivatives. 2020

Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt.

Two series of novel 1,2,4-triazol-3-yl-thioacetamide 3a-b and 4a-b and 5-pyrazin-2-yl-3H-[1,3,4]oxadiazole-2-thiones 9a-h were designed and synthesized. The compounds prepared have been identified using 1H NMR, 13C NMR and elemental analyses. The synthesized compounds 3a, 3b, 4a, 4b, 9a, 9b, 9d-e and 9f have been evaluated with α-difluoromethylornithine (DFMO) as a control drug for their in vitro antitrypanosomal activity against Trypanosoma brucei. Results showed that 3b was the most active compound in general and also more potent than control DFMO. 3b was 8 folds more potent than the reference with IC50 of 0.79 μM and IC90 of 1.35 μM, respectively compared to DFMO (IC50 = 6.10 μM and IC90 of 8.66 μM). The tested compounds showed moderate cytotoxicity with selectivity indices ranging from 12 (9d) to 102 (3b) against L6 cells. Docking study was performed into ten of T. brucei enzymes which have been identified as potential/valid targets for most of the antitrypanosomal agents. The results of the docking study revealed high binding scores toward many of the selected enzymes. A good correlation was observed only between log (IC50) of antitrypanosomal activity of the new compounds and their calculated Ki values against TryR enzyme (R2 = 0.726). Compound 3b, the most active as antitrypanosomal agents exhibited similar binding orientation and interaction to those of WP6 against TryR enzyme. However, in a next round of work, a complementary studies will be carried out to clarify the mechanism of action of these compounds.

UI MeSH Term Description Entries
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D014346 Trypanosoma brucei brucei A hemoflagellate subspecies of parasitic protozoa that causes nagana in domestic and game animals in Africa. It apparently does not infect humans. It is transmitted by bites of tsetse flies (Glossina). Trypanosoma brucei,Trypanosoma brucei bruceus,Trypanosoma bruceus,brucei brucei, Trypanosoma,brucei, Trypanosoma brucei,bruceus, Trypanosoma,bruceus, Trypanosoma brucei
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015800 Protozoan Proteins Proteins found in any species of protozoan. Proteins, Protozoan
D058886 Sterol 14-Demethylase An NADPH-dependent P450 enzyme that plays an essential role in the sterol biosynthetic pathway by catalyzing the demethylation of 14-methyl sterols such as lanosterol. The enzyme acts via the repeated hydroxylation of the 14-methyl group, resulting in its stepwise conversion into an alcohol, an aldehyde and then a carboxylate, which is removed as formic acid. Sterol 14-demethylase is an unusual cytochrome P450 enzyme in that it is found in a broad variety of organisms including ANIMALS; PLANTS; FUNGI; and protozoa. Sterol 14-Demethylases,CYP51 Cytochrome P-450,Cytochrome P-450 CYP51,Eburicol 14 alpha-Demethylase,Eburicol 14alpha-Demethylase,Lanosterol 14 alpha-Demethylase,Obtusifoliol 14alpha-Demethylase,Sterol 14-alpha-Demethylase,14 alpha-Demethylase, Eburicol,14 alpha-Demethylase, Lanosterol,14-Demethylase, Sterol,14-Demethylases, Sterol,14-alpha-Demethylase, Sterol,14alpha-Demethylase, Eburicol,14alpha-Demethylase, Obtusifoliol,CYP51 Cytochrome P 450,CYP51, Cytochrome P-450,Cytochrome P 450 CYP51,Cytochrome P-450, CYP51,Eburicol 14 alpha Demethylase,Eburicol 14alpha Demethylase,Lanosterol 14 alpha Demethylase,Obtusifoliol 14alpha Demethylase,P-450 CYP51, Cytochrome,P-450, CYP51 Cytochrome,Sterol 14 Demethylase,Sterol 14 Demethylases,Sterol 14 alpha Demethylase
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Evaluation of Biological Activity of Derivatives of 1,3,4-Thiadiazole, 1,3,4-Oxadiazole and 1,2,4-Triazole.
January 2021, Endocrine, metabolic & immune disorders drug targets,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Synthesis and Use of Pseudopeptides Derived from 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-based Dipeptidomimetics.
January 1999, Methods in molecular medicine,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Design and synthesis of novel phthalide derivatives containing 1,3,4-oxadiazole/1,2,4-triazole units as potential antifungal agents.
February 2024, Chemistry & biodiversity,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Synthesis and antiproliferative assay of 1,3,4-oxadiazole and 1,2,4-triazole derivatives in cancer cells.
April 2013, Drug discoveries & therapeutics,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Non-carboxylic analogues of naproxen: design, synthesis, and pharmacological evaluation of some 1,3,4-oxadiazole/thiadiazole and 1,2,4-triazole derivatives.
November 2007, Archiv der Pharmazie,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives.
January 1996, European journal of medicinal chemistry,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Synthesis of 1,2,4-triazole and 1,3,4-oxadiazole derivatives as inhibitors for STAT3 enzymes of breast cancer.
November 2023, Archiv der Pharmazie,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Synthesis and antimicrobial activity of new 1,2,4-triazole and 1,3,4-thiadiazole derivatives.
April 2008, Journal of enzyme inhibition and medicinal chemistry,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
Design, synthesis, and biological activity of novel 1,2,4-oxadiazole derivatives.
November 2020, BMC chemistry,
Montaser Sh Shaykoon, and Adel A Marzouk, and Osama M Soltan, and Amira S Wanas, and Mohamed M Radwan, and Ahmed M Gouda, and Bahaa G M Youssif, and Mohamed Abdel-Aziz
1,3,4-Oxadiazole and Heteroaromatic-Fused 1,2,4-Triazole Synthesis using Diverted Umpolung Amide Synthesis.
October 2017, Synthesis,
Copied contents to your clipboard!